Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Pfizer
(NY:
PFE
)
28.30
-0.41 (-1.43%)
Official Closing Price
Updated: 4:10 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Pfizer
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Pfizer to Buy a GLP-1 Drugmaker? Here's Why You Shouldn't Count on That Happening
August 01, 2024
Pfizer's debt load could inhibit the company's ability to take on acquisitions in the near term.
Via
The Motley Fool
Pfizer Just Did This for the First Time in 6 Quarters. Time to Buy?
August 01, 2024
Pfizer shares have advanced 20% over the past three months.
Via
The Motley Fool
The Top 7 Stocks to Buy Now: Summer 2024
July 31, 2024
Investors should give consideration to taking a position in one of these top stocks to buy that are flashing strong growth signals.
Via
InvestorPlace
Pfizer's Diverse Portfolio And Strong Execution Earn Analyst Praise Despite Patent Concerns
July 31, 2024
Pfizer reported second-quarter adjusted EPS of $0.60, surpassing the consensus of $0.46. Sales reached $13.28 billion, beating expectations. Analysts highlight Pfizer's robust portfolio, effective...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Pfizer's Options Frenzy: What You Need to Know
July 31, 2024
Via
Benzinga
Pfizer $PFE Beats Earnings Estimates
July 30, 2024
Pfizer $PFE Beats Earnings Estimates and Raises Full-Year Outlook Amid Cost-Cutting Measures
Via
Chartmill
(PFE) - Analyzing Pfizer's Short Interest
July 29, 2024
Via
Benzinga
Pfizer (PFE) Q2 2024 Earnings Call Transcript
July 30, 2024
PFE earnings call for the period ending June 30, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Bristol Myers, Johnson & Johnson, AbbVie, AstraZeneca Expect Minimal Impact From Upcoming Medicare Price Negotiations
July 30, 2024
Top pharmaceutical companies including Bristol Myers, Johnson & Johnson, AbbVie, and AstraZeneca foresee limited impact from the 2026 Medicare drug price cuts, easing initial industry concerns.
Via
Benzinga
Tech Stocks Drop Ahead Of Key Earnings; Nvidia Falls, CrowdStrike Hits 8-Month Low: What's Driving Markets Tuesday?
July 30, 2024
Investor sentiment took a hit on Tuesday as caution prevailed ahead of significant market events, including key tech earnings reports and the Federal Open Market Committee meeting.
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
July 30, 2024
Via
Benzinga
Stock Of The Day: Pfizer Pattern Offers Lessons After Better-Than-Expected Q2 Results
July 30, 2024
Like many things on Wall Street, technical analysis is widely misunderstood. Many analysts try to identify chart patterns without understanding the psychology and price action that creates them. This...
Via
Benzinga
Pfizer Records First Sales Growth In Its Post-Covid Era And It Owes It To Cancer
July 30, 2024
The market for vaccines and treatments used in managing COVID-19 has shrunk by billions of dollars a year. Forced to rebuild their business, pharmaceutical companies like Pfizer Inc (NYSE: PFE)...
Via
Benzinga
Exposures
COVID-19
PFE Stock Earnings: Pfizer Beats EPS, Beats Revenue for Q2 2024
July 30, 2024
PFE stock results show that Pfizer beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Dow Jumps 200 Points; Pfizer Earnings Top Views
July 30, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Pfizer Marks First Revenue Growth Since COVID Revenue Peak In 2022, Lifts Annual Guidance
July 30, 2024
Pfizer reports Q2 adjusted EPS of $0.60, beating the $0.46 consensus. Sales reached $13.28 billion, driven by acquired products and new launches, despite a decline in Comirnaty. Updated 2024 revenue...
Via
Benzinga
Exposures
COVID-19
Jim Cramer Says No To This Health Care Stock, Recommends Holding On To Constellation Energy: 'It's Up A Huge Amount'
July 30, 2024
Jim Cramer said Constellation Energy is a "solar play that is a very good company. It's up a huge amount versus a lot of other stocks."
Via
Benzinga
Pfizer Inc. Beats Q2 Market Expectations With $13.3 Billion In Revenue
July 30, 2024
Pfizer Inc. reported a strong Q2 performance in 2024, with total revenues reaching $13.3 billion.
Via
Talk Markets
Pfizer Stock Rises On Earnings Beat, Raised Outlook
July 30, 2024
The drug giant's EPS fell vs. a year earlier, but revenue topped.
Via
Investor's Business Daily
Topics
Earnings
Exposures
Financial
Top 2 Cheap Healthcare Stocks to Buy as Sector Outperforms
July 30, 2024
The healthcare sector, represented by the XLV ETF, has seen a resurgence, breaking out of a multi-year consolidation phase and surging almost 3% in July.
Via
MarketBeat
Topics
ETFs
Nasdaq, S&P Futures Rise As Microsoft, AMD Earnings Take Spotlight: Will Fed Provide 'Turbo Boost' For Market? Analyst Weighs In
July 30, 2024
Wall Street is likely to tenaciously hold onto the slender optimism ahead of a slew of earnings from notable companies and the Federal Reserve’s two-day rate-setting meeting that gets underway on...
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Pfizer Reports Strong Second-Quarter 2024 Results And Raises 2024 Guidance
July 30, 2024
From
Pfizer Inc.
Via
Business Wire
10 Best Ultra-High-Yield Dividend Stocks to Consider as Part of a Long-Term Portfolio
July 30, 2024
These ultra-high-yield dividend stocks could be a great fit for a long-term-oriented portfolio.
Via
The Motley Fool
Is Bristol Myers Squibb a Good Dividend Stock to Buy Now?
July 30, 2024
A lowered outlook for 2024 and upcoming patent expirations have investors concerned about this pharmaceutical giant's dividend program.
Via
The Motley Fool
Topics
Intellectual Property
Exposures
Intellectual Property
US Stocks Close Mixed Ahead Of Big Earnings, Fed Decision: Investor Optimism Improves Further
July 30, 2024
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Procter & Gamble, Microsoft And 3 Stocks To Watch Heading Into Tuesday
July 30, 2024
Via
Benzinga
Pfizer Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
July 30, 2024
Via
Benzinga
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 3% Dividend Yields
July 29, 2024
Via
Benzinga
How To Earn $500 A Month From Pfizer Stock Ahead Of Q2 Earnings
July 29, 2024
Pfizer Inc (PFE) expected to release Q2 financial results on Tuesday before opening bell. Analysts predict earnings at 46 cents/share, down from 67 cents last year. Stock gained 3.4% to close at $30.77...
Via
Benzinga
Prediction: This Will Be Pfizer's Next Big Move
July 29, 2024
One market in particular is too lucrative for it to miss out on any longer.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.